http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강보라,김지영,최준호,김지수,남석진,양정현1,김정한,Bo Ra Kang,Jiyoung Kim,Jun-Ho Choe,Jee Soo Kim,Seok Jin Nam,Jung-Hyun Yang1,Jung-Han Kim 대한갑상선-내분비외과학회 2013 The Koreran journal of Endocrine Surgery Vol.13 No.4
Purpose: Because the main drawback of bilateral adrenalectomy is permanent adrenal insufficiency and the subsequent risks of life-long steroid use, adrenal preserving partial adrenalectomy is being accepted as its alternative. The aim of this study is to investigate the indications for bilateral adrenalectomy and to assess the postoperative outcomes and steroid replacement according to operative methods. Methods: From May 1996 through July 2013, a total of 25 patients who underwent bilateral adrenalectomy in our institution were reviewed retrospectively. Surgical outcomes were compared between total and partial adrenalectomy, and postoperative steroid hormone replacement were examined according to the volume of remnant adrenal gland. Results: The median follow-up duration of 25 patients was 55.8 months. The most common indication for bilateral adrenalectomy was bilateral pheochromocytoma (n=16), which was associated with genetic mutation of RET or VHL gene in 11 cases. Cushing's syndrome (n=8) and hyperaldosteronism (n=1) were another indications of bilateral adrenalectomy. Total adrenalectomy was performed in 8 patients and adrenal preserving partial adrenalectomy in 17 patients. Among the 17 patients, only 5 patients needed adrenal hormone replacement and 2 patients had a recurrence at remnant adrenal tissue. Conclusion: Adrenal preserving partial adrenalectomy might be a better option for bilateral adrenal tumor than total adrenalectomy because it can reduce complications associated with adrenal insufficiency and recurrence of the disease is not common.
Yang, Yoon Jung,Hwang, Se Hee,Kim, Hyun Ja,Nam, Seok-Jin,Kong, Gu,Kim, Mi Kyung Lawrence Erlbaum Associates, Publishers [etc.] 2010 Nutrition and cancer Vol.62 No.5
<P>Nitrate is a precursor in the endogenous formation of N-nitroso compounds, which are potent animal carcinogens, whereas antioxidant vitamins have been suggested to protect against carcinogenesis. Interestingly, nitrate and antioxidant vitamins stem from the same dietary sources. We investigated whether the intake of nitrate relative to antioxidant vitamins is associated with the risk of breast cancer. A total of 362 breast cancer cases were matched to the 362 controls by age and menopausal status. Dietary intake was assessed using a quantitative food frequency questionnaire with 121 food items by trained interviewers. The nitrate to antioxidant vitamin consumption ratio was then calculated. Conditional logistic regression analysis was used to obtain odds ratios (ORs) and corresponding 95% confidence intervals (CI). Mean intakes of nitrate for cases and controls were 421 mg/day and 424 mg/day, respectively. Intakes of nitrate, nitrate/beta-carotene, nitrate/vitamin C, and nitrate/vitamin E were not associated with breast cancer risk. However, higher breast cancer risk was observed with higher intake of nitrate/folate (OR = 2.03, 95% CI = 1.16-3.54, P for trend = 0.052). Our results suggest that lowering the ratio of nitrate to folate intake may be effective in reducing breast cancer risk.</P>
Diagnosis of failure modes for all-solid-state Li-ion batteries enabled by three-electrode cells
Nam, Young Jin,Park, Kern Ho,Oh, Dae Yang,An, Woo Hyun,Jung, Yoon Seok The Royal Society of Chemistry 2018 Journal of Materials Chemistry A Vol.6 No.30
<P>Bulk-type all-solid-state Li-ion batteries have emerged as the enabler to achieve better safety and to use Li metal negative electrodes for higher energy density. However, all-solid-state half-cells fabricated using In or Li-In counter electrodes (CEs) have been routinely tested to assess working electrodes (WEs) without any verification. Moreover, there have been few reports on the in-depth analysis of all-solid-state full-cells, which is imperative for practical applications. In this work, for the first time, we report novel bulk-type all-solid-state three-electrode cells that enable successful deconvolution and diagnosis of the voltages of positive and negative electrodes even for cells having thin solid electrolyte (SE) layers. In the first case study, that of Sn/Li-In half-cells, earlier termination of Li-In CEs than Sn WEs, which results in unexpectedly low capacity, is measured. This problem is solved by percolating Li-In with SEs. For the second case, namely, that of LiNi0.6Co0.2Mn0.2O2/graphite full-cells having only 50-60 μm-thick SE layers (which are fabricated by a scalable wet-slurry process), internal short circuits by penetrating growth of Li metal during charging at high C-rates are revealed for the first time. Further, a unique dischargeability to 0 V for LiNi0.6Co0.2Mn0.2O2/graphite or LiNi0.6Co0.2Mn0.2O2/Si-C full-cells is described.</P>
( Seok-Hwan Kim ),( Myeong Jun Song ),( Jung Hyun Kwon ),( Sun Hong Yoo ),( Soon Woo Nam ),( Hee Yeon Kim ),( Chang Wook Kim ),( Chan Ran You ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung W 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: To evaluate the efficacy and safety of direct antiviral agents (DAAs) available in chronic kidney disease (CKD) patients with chronic hepatitis C (HCV) in Korea. Methods: In a retrospective, multicenter study involving 8 medical institutions, 362 patients were enrolled from 2015 to 2019. The efficacy and safety of DAAs including glecaprevir/pibrentasvir, sofosubvir/ribavirin, ledipasvir/sofosbuvir, and daclatasvir/ asunaprevir were analyzed for patients according to CKD stage. We evaluated sustained virologic response at week 12 after treatment (SVR12) as primary endpoint. The efficacy and adverse events were also evaluated according to CKD stage. Results: Among 362 patients, 308 patients completed DAA treatment and follow-up period after end of treatment. The subjects comprised 87 patients (62 with CKD stage 3 and 25 with CKD stage 4-5), of whom 22 were undergoing hemodialysis. HCV patients with CKD stage 1 and 2 (eGFR>60) showed SVR12 of 98.1% and 95.5% respectively. SVR12 of CKD stage 3 and 4-5 (eGFR<60) patients was 91.9% and 88% respectively. All patients undergoing hemodialysis achieved SVR12 (90.9%). Treatment failure and cessation of DAAs was 2.7% (3/110) and 0% in stage 1, 2.6% (3/113) and 1.7% (2/113) in stage 2; 1.6% (1/62) and 6.4% (4/62) in stage 3 ; 4% (1/25) and 8% (2/25) in stage 4-5. Conclusions: DAAs shows favorable SVR12 and safety with CKD patients (eGFR< 60) with HCV compared with patients with eGFR >60. The efficacy and safety of DAAs may be related with duration of treatment and concomitant medications. Therefore, it is important to select adequate regimens of DAAs and to treat CKD patients with HCV properly.
( Jung Hyun Kwon ),( Sun Hong Yoo ),( Soon Woo Nam ),( Hee Yeon Kim ),( Chang Wook Kim ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( Seok-hwan Kim 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: A real-life study is essential for the investigation of treatment outcomes outside the clinical trials. The aim is to evaluate the efficacy and safety of interferon free regimen for patients with hepatitis C virus (HCV)-1b in real-practice. Methods: 591 HCV-1b patients who received interferon free regimen at the liver unit of the Catholic University of Korea were consecutively recruited and analyzed. Results: Among 591 patients, 518 patients started the daclatasvir and asunaprevir 24 weeks regimen, 61 patients ledipasvir-sofosbuvir 12 weeks regimen and 12 patients daclatasvir and sofosbuvir 12 weeks regimen. The sustained virologic response (SVR) 12 was 95.6% (261/273) in the daclatasvir and asunaprevir group, 93.8% (15/16) in the ledipasvir-sofosbuvir group and 100% (4/4) in the daclatasvir and sofosbuvir group. Resistant-associated variant (RAV) of NS5A loci test was performed in 575 patients. Among them, L31 or Y93 was positive in 57 patients (9.9%) and the RAV was “undetermined” in 21 patients (3.7%). In the daclatasvir and asunaprevir group, the SVR12 in the RAV positive patients was 25.0% (1/4) compared to 96.4% (239/248) and 100% (12/12) in those with RAV negative and “undetermined”, respectively (P=0.000). However, there was no difference in SVR12 according to the RAV test results in ledipasvir-sofosbuvir and daclatasvir-sofosbuvir groups. No difference of SVR12 was observed according to prior treatment experience, the presence of cirrhosis and chronic kidney disease (GFR ≤ 60 ml/min/1.73 m2), old age (≥ 70 year-old), and high baseline viral load (≥ 800,000 IU/ml). Overall, all the regimens were well-tolerated but 18 (3.0%) patients discontinued treatment due to possible-drug related side effects and breakthrough. Conclusions: Interferon free regimens in genotype 1b HCV infected Korean patients resulted in high SVR rates. This multicenter cohort study represents the efficacy and tolerability of DAA treatment in genotype 1b HCV infected Korean patients in real clinical settings.